Simone Fishburn, Editor in Chief of BioCentury, Selina Koch, Executive Editor, and Lauren Martz, Executive Director of Biopharma Intelligence, discuss major trends in biopharma. They highlight the shift towards human-first, causal biology aimed at improving drug translation. Key topics include immunoproteomics outpacing genomics in inflammation and immunology target discovery. The trio also explores advancements in neuroscience, emphasizing how precision medicine can validate targets using biomarkers, ultimately reshaping clinical approaches in drug development.
